This research demonstrates that lactobacillus plantarum and lactobacillus delbrueckii reduce inflammation in colitis, suggesting a potential treatment for IBD.
Key Points
Probiotic treatment in rats significantly reduced inflammation and improved mucosal health.
Both probiotic strains improved key inflammatory markers, indicating potential for IBD therapy.
Histopathological analyses revealed decreased crypt abscesses and inflammatory cell infiltration.
Mesalazine showed limited effects in comparison to the probiotics in improving colitis symptoms.